|
|
|
Glenmark Pharmaceuticals Limited |
|
Glenmark Pharmaceuticals Limited was founded by Mr. Gracias Saldanha on 18th November 1977 with a capital of Rs. 1 million and a staff of just three. In 1979 Glenmark launched its first product, Candid Cream (Clotrimazole), in topical antifungal dermatology segment.
Glenmark Pharmaceuticals Limited has its headquarters in Mumbai and enjoys global presence in regulated international markets as well. The company is into the business of manufacturing and marketing of formulation products and active pharmaceutical ingredients (API). It supplies APIs to about 45 markets and formulations to about 70 markets worldwide. It has formulations manufacturing plants in Goa, Nasik, Baddi and Sao Paolo (Brazil) and API manufacturing plants in Kukumbh, Solapur and Ankleshwar.
|
|
Glenmark's R&D centre in Mumbai has intellectual property of over 350 scientists. The R&D team of Glenmark has developed a novel drug lead for asthma and COPD in a short span of three years. Apart from scientists, it has about 1700 medical representatives.
Glenmark has been visiting the premier institutes across the country to grab the best talent from there. Some of the institutes visited by the company are as follows:
- IIM-Ahmedabad
- IIM-Bangalore
- IIM-Kolkata
- IIM-Indore
- IIFT
- MDI
- NITIE
- SCMHRD
Board of Directors
Mr. Gracias Saldanha, Chairman & Non-Executive Director
Mrs. B. E. Saldanha, Non-Executive Director
Mr. Glenn Saldanha, Managing Director & CEO
Mrs. Cheryl Pinto, Director - Corporate Affairs
Mr. Abhinna Sundar Mohanty, Director - Domestic Formulations
Mr. R. V. Desai, Director - Finance, IT & Legal
Mr. Julio F. Ribeiro, Non-Executive Director
Mr. Natvarlal B. Desai, Non-Executive Director
Mr. M. Gopal Krishnan, Non-Executive Director
Mr. Sridhar Gorthi, Non-Executive Director
Products
Initially Glenmark was manufacturing and marketing formulations within India only. Then it started expanding its business to semi-regulated markets. It started bulk drug business in 2001. The product segment in formulations covers dermatology, pediatrics, ENT, internal medicine, diabetes and gynaecology.
It has "Branded generics" in the semi-regulated markets of Asia, Latin America, Africa and Russia/CIS whereas "Generics" in the regulated market of EU and USA.
The company's domestic API and co-marketing operations have achieved a record growth of over 60%. They have grown to Rs.713.4 million in 2004-05 from Rs. 445.3 million in 2003-04.
Contact Address:
Glenmark Pharmaceuticals Limited
Glenmark House
HDO-Corporate Building, Wing -A
B. D. Sawant Marg
Chakala, Off Western Express Highway
Andheri [East], Mumbai 400099
India
Tel.: [+91-22] 6758 9999
Fax: [+91-22] 6758 9986
Email: india_marketing@glenmarkpharma.com
Website: www.glenmarkpharma.com
|
|
|
|
|
|
|
|
|
|
